Investment
Features
FeesSafety
Academy
More
Pluang+

V2X stock drops 20% despite strong earnings and raised 2026 guidance, seen as a buy opportunity.

Company Fundamentals
15 Sep 2026
Seeking Alpha
View Source
Bullish
V2X stock drops 20% despite strong earnings and raised 2026 guidance, seen as a buy opportunity.

V2X, Inc. experienced a 20% stock sell-off despite reporting strong earnings and raising its full-year 2026 guidance for revenue, adjusted EBITDA, and EPS. The company maintains a robust backlog of $12.7 billion, recently secured two $500 million contracts, and shows double-digit growth in its Pacific theater segment. While risks include potential revenue impacts from the Iran conflict, V2X's diversification and AI-driven solutions position it well for future growth, making it an opportunistic buy for long-term investors at current prices of $65–$72.

V2X, Inc. is noted here with a robust $12.7 billion backlog as key context. For readers following the Industrials sector, here is Pluang's market snapshot as of Sep 15, 2026 20:44 WIB: out of 75 priced US Industrials stocks, 17 rose and 56 fell. Notable movers include LYFT at USD 15.62 with a 1-day change of -1.76%, TECK at USD 64.98 down 1.73%, and EH at USD 4.44 down 1.55%.

More News

Ascendis Pharma gains full rights to TransCon tech, launches $400M buyback, and posts positive trial data.

Ascendis Pharma gains full rights to TransCon tech, launches $400M buyback, and posts positive trial data.

Ascendis Pharma A/S regained full control of its TransCon technology for metabolic diseases from Novo Nordisk, allowing it to independently develop and sell treatments, including for obesity. The company also authorized a $400 million share repurchas...

Market News
Bullish
4 hours ago
Deutsche Bank upgrades AstraZeneca to Hold after mixed drug trial results.

Deutsche Bank upgrades AstraZeneca to Hold after mixed drug trial results.

Deutsche Bank upgraded AstraZeneca's stock rating from Sell to Hold following mixed results from its drug trials. The lung disease drug tozorakimab showed strong Phase III results and received FDA priority review, signaling potential future growth. H...

Analyst Insights
Neutral
4 hours ago
Alphabet shares seen with 50% upside as its Cloud growth outpaces cheap valuation

Alphabet shares seen with 50% upside as its Cloud growth outpaces cheap valuation

Alphabet's stock is undervalued with a 50% upside potential, trading at a low P/E of 17 despite rapid growth, especially in its Cloud segment which grew 82% year-over-year with a $514 billion backlog. The company reported strong Q2 2026 earnings, bea...

Analyst Insights
Bullish
4 hours ago
ASML shares drop 14% but remain a strong buy with robust AI-driven growth and a $45B order backlog.

ASML shares drop 14% but remain a strong buy with robust AI-driven growth and a $45B order backlog.

ASML's stock fell over 14% recently, yet it remains a strong buy due to its monopoly on EUV lithography machines essential for advanced chip manufacturing. The company reported a 21.3% revenue increase in Q2 2026 and raised its full-year guidance, su...

Analyst Insights
Bullish
4 hours ago
Shengfeng reports 18.4% revenue growth in H1 2026, driven by expanded logistics services.

Shengfeng reports 18.4% revenue growth in H1 2026, driven by expanded logistics services.

Shengfeng Development Limited announced an 18.4% increase in revenue to $311.8 million for the first half of 2026, mainly due to growth in transportation services and expanded client partnerships. Gross profit rose 11.3%, though gross margin slightly...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App